Clinical trial

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630

Study summary

ClinicalTrials.gov

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention L-Ornithine L-Aspartate Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention CDK4/6 inhibitor Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrant View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention N-Acetylcysteine (NAC) Treatment Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pioglitazone (PIO) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention PARP inhibitor Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-09-25

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

L-Ornithine L-AspartateDRUG

CDK4/6 inhibitorDRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

N-Acetylcysteine (NAC) TreatmentDRUG

Pioglitazone (PIO)DRUG

PARP inhibitorDRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07117630 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.